Gynecologic Cancer Early Detection

Cervical, endometrial & ovarian
cancer methylation testing

Three non-invasive, NMPA-registered tests — CISCER® for cervical cancer and HPV-positive triage, CISENDO® for endometrial cancer, CISOVA® for ovarian cancer.

Our Vision

Accurate, leaving no lesion hidden

Accessible, bringing screening within reach

Non-invasive, giving women peace of mind

Making gynecologic cancer early screening accessible to every woman through methylation innovation.

Strength & Achievements

Building professional trust through evidence-based data

900 m²
GMP Production Facility
1000 m²
R&D Laboratory
10M+/yr
Annual Testing Capacity
8 patents
Domestic & International Patents
3 products
NMPA-Registered Products
Research

Evidence-based, continuously innovating

Conducting multiple prospective multi-center clinical trials with numerous publications, advancing methylation applications through evidence.

Guidelines

Recommended by multiple guidelines and consensus

Multiple national clinical guidelines and expert consensus statements support the standardized clinical application of our products.